Key facts
- Neurenati Therapeutics’s last known valuation is $6.4M (Sep 2025).
- It has raised $4.3M; the latest was Seed Round ($2.2M) in Sep 2025.
- Notable investors include Investissement Quebec, Francois Ravenelle, Genson Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Neurenati Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurenati Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurenati Therapeutics
Developer of novel regenerative therapies intended for the treatment of Hirschsprung disease. The company focuses on developing innovative therapy via growth factor to treat newborns with Hirschsprung disease, a life-threatening gastrointestinal birth defect, providing doctors with a non-surgical alternative to treat rare GI diseases in newborns.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2020
- Employees
- 5
- Website
- neurenati.com/
- Ownership
- Privately Held (backing)
Neurenati Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurenati Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurenati Therapeutics in its N-PORT filings yet. We sweep new filings monthly.